Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALBUMINUS low-dose versus standard-dose human albumin during large-volume paracentesis in cirrhosis
NL-OMON61295Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of albumin (human) in Cirrhosis and ascites (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary composite liver-related decompensation endpoint. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
albumin (human)
03
Conditions
Cirrhosisascites
Beyond the preview
Go deeper on NL-OMON61295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61295.